See today's BioWorld New hires and promotions in the biopharma industry, including: Amylyx, Beigene, Blossomhill, Halia, Iambic, Perspective, Portage, Septerna, Unity. Amylyx Pharmaceuticals Inc., of Cambridge, Mass., named Dan Monahan chief commercial officer....

Utah Business is proud to present the 2024 Year in Review. This recap features notable news, M&A activity and closed funding rounds within Utah’s business community in January 2024.  By Mekenna Malan, Melanie Jones and Savannah Beth Withers Taylor Jan 3, 2025...

Read this article on the website US biotech Halia Therapeutics has announced promising topline findings from its ongoing Phase 2 clinical trial of its oral treatment for lower-risk myelodysplastic syndromes. The drug, HT-6184, targets the NEK7 protein, which is...

Read this article on the website Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initialpositive data in patients with an early form of blood cancer that affects the bone marrow. The Utah-based biotech is investigating...

https://slenterprise.com/index.php/news/7714-industry-briefs-10-21-24 RECOGNITIONS This year’s PharmaVoice 100 honorees list includes David Bearss, CEO, president and co-founder of Halia Therapeutics, a Lehi-based company developing therapies addressing chronic...

Combination with NLRP3 inhibitor achieves 50% greater weight loss and lean muscle preservation in mice than with semaglutide alone. As featured in Longevity.Technology "Inflammation-targeting biotech Halia Therapeutics has reported promising preclinical results from a...

https://podcast.labiotech.eu/1995493/episodes/15734215-targeting-inflammation-a-revolution-in-disease-treatment Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders....

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity."...

By Jill Drachenberg -- BioSpace July 15, 2024 Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression. Preventing or reversing neuroinflammation could be the next clinical...

Charleston, South Carolina, June 5, 2024 – John Kauwe Ph.D., a 2013 CCAD awardee shares how CCAD made a difference in his research career. Kauwe is the president of BYU-Hawaii and owner of Halia Therapeutics, a company that discovers and develops novel...

By Joe Petroziello -- Pharmaceutical Executive June 13, 2024 Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions. During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia...

Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the inflammatory...

Venture Capital Podcast has released their Founder 100 honoree list for Utah. It is a crowd-nominated, peer-voted list of the state's top founders in terms of their attractiveness to investors. The honorees and a large group of investors will meet this evening in a...